Pasithea Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Pasithea Therapeutics Corp
KTTA Stock  USD 0.70  0.03  4.11%   
Pasithea Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Pasithea Therapeutics' valuation are provided below:
Gross Profit
-2.2 K
Market Capitalization
5.4 M
Enterprise Value Revenue
277.4414
Revenue
486.6 K
Earnings Share
(10.60)
We have found one hundred eleven available trending fundamental ratios for Pasithea Therapeutics, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Pasithea Therapeutics recent market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. As of August 2, 2025, Market Cap is expected to decline to about 3.8 M. The current year's Enterprise Value is expected to grow to about (3.8 M)
Check Pasithea Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pasithea Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 681.5 K, Interest Expense of 224 or Other Operating Expenses of 11 M, as well as many indicators such as Price To Sales Ratio of 36.39, Dividend Yield of 83.34 or PTB Ratio of 2.0E-4. Pasithea financial statements analysis is a perfect complement when working with Pasithea Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Pasithea Stock
Check out the analysis of Pasithea Therapeutics Correlation against competitors.

Pasithea Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets31 M16.1 M10.9 M
Slightly volatile
Other Current Liabilities959.6 K1.1 M336.7 K
Slightly volatile
Total Current Liabilities1.3 M1.1 M468.1 K
Slightly volatile
Total Stockholder Equity15.5 B14.8 B1.9 B
Slightly volatile
Net Tangible Assets62.1 M59.1 M17.4 M
Slightly volatile
Accounts Payable3.1 M2.9 M660.7 K
Slightly volatile
Cash6.6 M6.9 M7.4 M
Slightly volatile
Cash And Short Term Investments6.6 M6.9 M7.4 M
Slightly volatile
Common Stock Shares Outstanding1.2 M1.1 M844.2 K
Slightly volatile
Liabilities And Stockholders Equity31 M16.1 M10.9 M
Slightly volatile
Other Current Assets469.4 K445.6 K165.4 K
Slightly volatile
Other Stockholder Equity67.7 B64.4 B8.3 B
Slightly volatile
Total Liabilities1.9 M1.3 M659 K
Slightly volatile
Net Invested Capital29.1 M14.8 M10.2 M
Slightly volatile
Total Current Assets7 M7.4 M7.6 M
Slightly volatile
Capital Stock13213912.5 K
Slightly volatile
Net Working Capital5.9 M6.2 M7.1 M
Slightly volatile
Common Stock13213912.5 K
Slightly volatile
Other Liabilities1.2 M1.3 M1.4 M
Slightly volatile
Property Plant And Equipment Gross156.5 K164.7 K131.7 K
Slightly volatile
Property Plant Equipment16.1 K18.1 K19.7 K
Slightly volatile
Short and Long Term Debt Total69.8 K73.5 K767.2 K
Slightly volatile
Net Receivables34.6 K36.5 K252.5 K
Slightly volatile
Short Term Debt96.8 K73.5 K146 K
Slightly volatile
Intangible Assets6.4 M7.3 M8.3 M
Slightly volatile
Other Assets0.80.90.9813
Slightly volatile
Short Term Investments5.5 B6.2 B6.8 B
Slightly volatile

Pasithea Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization681.5 K649 K166.4 K
Slightly volatile
Other Operating Expenses11 M14.2 M3.8 M
Slightly volatile
Total Operating Expenses10.8 M13.6 M3.8 M
Slightly volatile
Selling General Administrative6.7 M7.1 M497.3 M
Slightly volatile
Cost Of Revenue392.7 K649 K125.7 K
Slightly volatile
Reconciled Depreciation330.1 K649 K96.6 K
Slightly volatile
Selling And Marketing Expenses9.5 B9.1 B1.7 B
Slightly volatile

Pasithea Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation19.8 M18.9 M2.5 M
Slightly volatile
End Period Cash Flow7.3 B6.9 B893.5 M
Slightly volatile
Change To Liabilities532.1 K506.8 K154.4 K
Slightly volatile
Stock Based Compensation734.9 K773.7 K536.9 K
Slightly volatile
Begin Period Cash Flow17.1 B16.3 B2.1 B
Slightly volatile
Issuance Of Capital Stock31 M24.4 M44.5 M
Slightly volatile
Dividends Paid287.7 M323.7 M352.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio36.3938.312 K
Slightly volatile
Dividend Yield83.3493.75102
Slightly volatile
PTB Ratio2.0E-42.0E-4140
Slightly volatile
Book Value Per Share17.7213.48688.2478
Slightly volatile
Average Payables1.9 M1.8 M589.1 K
Slightly volatile
Stock Based Compensation To Revenue1.881.9723.9207
Slightly volatile
Capex To Depreciation0.05780.060815.8343
Very volatile
PB Ratio2.0E-42.0E-4140
Slightly volatile
Payables Turnover0.240.230.079
Slightly volatile
Sales General And Administrative To Revenue16.3218.3620.0134
Slightly volatile
Research And Ddevelopement To Revenue4.384.935.3752
Slightly volatile
Capex To Revenue2.333.962.0133
Slightly volatile
Cash Per Share6.06.31596.3404
Slightly volatile
Days Payables Outstanding1.6 K1.7 K7.7 K
Slightly volatile
Income Quality1.1 K1 K129
Slightly volatile
Intangibles To Total Assets0.30.53370.2513
Slightly volatile
Net Debt To EBITDA0.50.52239.1061
Slightly volatile
Current Ratio6.256.579635.5973
Pretty Stable
Tangible Book Value Per Share5.385.66446.0441
Slightly volatile
Shareholders Equity Per Share14.2 K13.5 K1.7 K
Slightly volatile
Debt To Equity0.00380.0040.0184
Slightly volatile
Capex Per Share0.02320.02450.1246
Pretty Stable
Graham Net Net4.895.14625.8212
Slightly volatile
Revenue Per Share0.360.350.1024
Slightly volatile
Interest Debt Per Share0.05530.05830.0574
Slightly volatile
Debt To Assets0.00340.00360.0173
Slightly volatile
Enterprise Value Over EBITDA0.250.26182.1773
Slightly volatile
Price Book Value Ratio2.0E-42.0E-4140
Slightly volatile
Days Of Payables Outstanding1.6 K1.7 K7.7 K
Slightly volatile
Ebt Per Ebit0.70.97580.9419
Slightly volatile
Company Equity Multiplier0.0010.00110.9075
Slightly volatile
Total Debt To Capitalization0.00380.0040.018
Slightly volatile
Debt Equity Ratio0.00380.0040.0184
Slightly volatile
Quick Ratio6.256.579635.5983
Pretty Stable
Net Income Per E B T0.790.930.9806
Slightly volatile
Cash Ratio5.876.181735.014
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.141.11.0266
Slightly volatile
Price To Book Ratio2.0E-42.0E-4140
Slightly volatile
Fixed Asset Turnover0.630.450.6774
Slightly volatile
Enterprise Value Multiple0.250.26182.1773
Slightly volatile
Debt Ratio0.00340.00360.0173
Slightly volatile
Price Sales Ratio36.3938.312 K
Slightly volatile
Asset Turnover0.01020.00970.0028
Slightly volatile
Price Fair Value2.0E-42.0E-4140
Slightly volatile

Pasithea Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.8 M4 M38 M
Slightly volatile

Pasithea Fundamental Market Drivers

Cash And Short Term Investments6.9 M

Pasithea Upcoming Events

12th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Pasithea Therapeutics Financial Statements

Pasithea Therapeutics stakeholders use historical fundamental indicators, such as Pasithea Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Pasithea Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pasithea Therapeutics' assets and liabilities are reflected in the revenues and expenses on Pasithea Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pasithea Therapeutics Corp. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-2.3 M-2.4 M
Cost Of Revenue649 K392.7 K
Stock Based Compensation To Revenue 1.97  1.88 
Sales General And Administrative To Revenue 18.36  16.32 
Research And Ddevelopement To Revenue 4.93  4.38 
Capex To Revenue 3.96  2.33 
Revenue Per Share 0.35  0.36 
Ebit Per Revenue(27.41)(28.78)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
USOICredit Suisse X Links
ULTYTidal Trust II
CONYYieldMax N Option
When determining whether Pasithea Therapeutics is a strong investment it is important to analyze Pasithea Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pasithea Therapeutics' future performance. For an informed investment choice regarding Pasithea Stock, refer to the following important reports:
How To Invest In Pasithea
Details
Is Pasithea Stock a good investment?
Details
What is Pasithea Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Pasithea Therapeutics Correlation against competitors.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pasithea Therapeutics. If investors know Pasithea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pasithea Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(10.60)
Revenue Per Share
0.37
Quarterly Revenue Growth
14.981
Return On Assets
(0.47)
Return On Equity
(0.83)
The market value of Pasithea Therapeutics is measured differently than its book value, which is the value of Pasithea that is recorded on the company's balance sheet. Investors also form their own opinion of Pasithea Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pasithea Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pasithea Therapeutics' market value can be influenced by many factors that don't directly affect Pasithea Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Please note, there is a significant difference between Pasithea Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pasithea Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pasithea Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY